

Reig Jofre reaches a new milestone: **5 million vials of injectable Remifentanil** marketed in Japan



Delegations representing Reig Jofre, Kern Pharma, Maruishi Pharma, Daiichi Sankyo and CBC. Osaka, Japan

- Commemoration of this important milestone, which was reached thanks to the collaboration between Reig Jofre, Kern Pharma, Maruishi Pharma, Daiichi Sankyo and CBC
- Reig Jofre is one of the world's largest producers of Remifentanil, the latest generation injectable anesthetic for hospital use

Barcelona (Spain), January 27, 2020, Reig Jofre, a pharmaceutical company quoted on the Spanish continuous market, marked the closure of 2019 with an important milestone; the manufacture and marketing in Japan of the 5 millionth unit of Remifentanil vials, a new generation injectable anesthetic for hospital use. The product was developed internally by the company and is produced in its lyophilized injectables plant in Barcelona.



The celebration of this milestone took place in the Japanese city of Osaka, with the presence of representatives from the pharmaceutical companies that made this achievement possible: **Reig Jofre**, which contributed its expertise in the development and manufacture of sterile lyophilized injectables; **Kern Pharma**, with its capacity to synthesize the active substance in its Terrassa plant (Barcelona, Spain); **Maruishi Pharmaceutical** (Osaka), project leader and expert in hospital specialties and disinfectants/antiseptics and which, in conjunction with **Daiichi Sankyo**, is responsible for the commercialization of Remifentanil throughout the Japanese hospital network; and **CBC**, a trader specialized in the generation of business opportunities in Japan.

The event was also attended by Yuko Kijimoto, **Director of the Catalan Network of Trade and Investment Offices** (Acció) in Tokyo, which in 2015 facilitated the initiation of commercial relations between companies from the two countries within the framework of a multi-sector mission.

Jorge Toledo Albiñana, the **Spanish ambassador to Japan**, hosted a reception for the Spanish and Japanese delegations at the embassy in Tokyo and participated in the ceremony electronically, highlighting the recent 150th anniversary of the establishment of diplomatic and commercial relations between Japan and Spain.

Reig Jofre produces **25% of the global supply** of remifentanil injectable vials in its sterile and lyophilized injectables plant in Barcelona and expects to significantly increase the supply of this anesthetic in Japan in the coming years, thanks to the capacity and knowledge of Maruishi in this area.

The Asian markets, which accounted for 7% of total sales in 2018 (official data until the publication of 2019 closure on February 28, 2020), are of special interest to the company for their size and growth potential.

For the marketing of its developments, Reig Jofre has its own sales network in 7 countries in Europe and South-east Asia, with more than 130 business partners (distributors and licensees) in 70 countries throughout the world.

Receive updated news about Reig Jofre by registering with the company's **subscription centre** via our corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a pharmaceutical company listed on the Spanish Stock Exchange's continuous market and dedicated to the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig



Jofre structures its product development activity in three business areas: (1) pharmaceutical technologies specialized in the development and manufacture of sterile and lyophilized injectable pharmaceutical products, as well as antibiotics derived from penicillin; (2) specialty products focused on the research, development, manufacture and commercialization of specialties in, above all, the areas of (i) skin, hair and nail health, (ii) joint health and pain, and (iii) women's health and, (3) Consumer Healthcare, in relation to which special mention may be made of the line of nutritional supplements, marketed under the brand Forté Pharma mostly in France, Belgium, Spain and Portugal, as well as other OTC products. Reig Jofre has more than 1000 employees, 4 development and production centres in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), direct sales in 7 countries and more than 130 business partners in 70 countries around the world. The company closed 2018 with a turnover of 181 million euros. Reig Jofre is quoted on the Spanish stock exchange's continuous market under the ticker RJF. Share capital: 76,062,457 shares

Further information

Inma Santa-Pau - Director of Communication and Investor Relations
Tel. (+34) 935 450 078 - inma.santapau@reigjofre.com
www.reigjofre.com